It was previously reported that CYP2B6 mRNA expression was decreased in hepatocellular carcinoma (HCC), and contrary, significantly increased in HBV and alcoholic cirrhosis, as well as in NAFLD [8, 22]. The gene discussed is CYP2B6; the disease is metabolic dysfunction-associated steatotic liver disease.